|drug2946||SARS-CoV-2 IgG Antibody Testing Kit Wiki||1.00|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
This is a randomized, double-blind, placebo-controlled, multicenter, 28-day study of adult participants hospitalized with COVID-19, with a safety follow-up telephone call at Day 60.
Description: Respiratory improvement is defined as sustained peripheral oxygen saturation (SpO2) ≥94% on room air.Measure: Time from Randomization to Respiratory Improvement Time: up to Day 28
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports